Novavax, Inc. — Q1 2022 Form 10-Q
Business context and reporting period. Unaudited results for the three months ended March 31, 2022, compared with Q1 2021. Novavax is a biotechnology company; during the quarter it began commercial shipments of its COVID-19 vaccine, NVX-CoV2373 (Nuvaxovid). The vaccine had received authorizations in multiple markets, while U.S. authorization remained pending. All amounts below are U.S. dollars.
Financial results and position
| Metric | Q1 2022 | Q1 2021 |
|---|---|---|
| Revenue | $704.0 million | $447.2 million |
| Product sales | $585.6 million | None |
| Grant revenue | $99.3 million | $446.9 million |
| Royalties and other revenue | $19.0 million | $0.3 million |
| Operating expenses | $494.7 million | $655.9 million |
| Operating income (loss) | $209.3 million | ($208.6 million) |
| Net income (loss) | $203.4 million | ($222.7 million) |
| Basic / diluted EPS | $2.66 / $2.56 | ($3.05) / ($3.05) |
| Operating cash flow | ($88.5 million) | $663.1 million |
| Cash, cash equivalents and restricted cash, quarter-end | $1.584 billion | $2.029 billion |
- Cost of sales was $15.2 million, or 3% of product sales. Management estimates approximately $0.7 billion of commercial inventory costs were expensed before approval; on an estimated standard-cost basis, adjusted cost of sales would have been about $160 million, or 27% of product sales. The adjusted figure is a non-GAAP measure.
- Cash and cash equivalents were $1.571 billion; current assets were $2.347 billion and current liabilities $2.261 billion. Deferred revenue totaled $1.536 billion, including $1.094 billion current and $441.7 million non-current.
- Convertible notes had $325 million principal and $323.8 million carrying value; classified as current at March 31, 2022 and due February 1, 2023. The notes bear 3.75% coupon interest. The company reported no additional material debt.
- Stockholders’ equity was $65.3 million, versus a $351.7 million deficit at year-end 2021. The company issued 2.2 million shares for $179.4 million net proceeds during the quarter.
Material changes and management commentary
- Revenue increased $256.7 million, principally as commercial vaccine sales began, partly offset by lower development activity and grant revenue. Product sales replaced grants as the largest revenue source.
- R&D expense fell $209.2 million to $383.5 million, primarily due to lower NVX-CoV2373 development costs. SG&A rose $32.8 million to $96.0 million, mainly from professional fees supporting the vaccine program.
- Net income improved by $426.1 million year over year, reflecting commercial sales and lower expenses. Operating cash flow nevertheless was negative, as the company applied prior advance purchase agreement prepayments to deliveries and had cash outflows for inventory, receivables and accrued liabilities.
- Management expected 2022 revenue to increase significantly versus 2021, driven by product sales, partner royalties and continued program funding. It expected R&D expense to decrease year over year as some manufacturing costs are capitalized, while SG&A and capital expenditures were expected to increase.
- Unsatisfied or partially unsatisfied performance obligations were approximately $7 billion; management expected the remaining obligations to be fulfilled in less than 12 months. Timing depends on manufacturing, deliveries, authorizations and, for grants, research and clinical results.
Outlook, risks and unusual items
- Novavax reported that Gavi notified it of an intent to seek changes to the quantity and timing of doses under its supply agreement. Novavax had not received an order from Gavi as of the filing, and future order timing and quantities were unclear. The agreement involves Novavax’s planned supply of 350 million doses; the broader COVAX commitment, including partner SIIPL, is 1.1 billion doses.
- Failure to meet regulatory, volume or delivery commitments could lead to refunds or reduced payments on advance prepayments and materially affect financial results. Manufacturing capacity, supply availability, regulatory review and demand remain important execution risks. The filing also cites foreign-exchange exposure and no existing currency hedges.
- The company’s U.S. government partnership had an instruction requiring alignment with FDA on analytical methods before additional U.S. manufacturing; in April 2022 the deadline was extended to July 2022. The FDA scheduled an advisory committee review for June 7, 2022. These are subsequent events, not Q1-period results.
- In April 2022, Japan approved the vaccine through partner Takeda; further authorizations and adolescent-use decisions were also reported. Initial Phase 1/2 combination COVID-influenza vaccine results were described as feasible, well tolerated and immunogenic; management expected to begin Phase 2 by year-end 2022.
- Par Sterile Products initiated arbitration alleging breach of a manufacturing-services agreement. The matter was preliminary and potential loss was not reasonably estimable; an adverse outcome could materially affect the company. Securities class and derivative lawsuits also remained pending, alleging misleading statements concerning manufacturing and regulatory approval. The company said it intended to defend the matters.
- Management reported disclosure controls were effective at the reasonable-assurance level and no material changes to internal control over financial reporting during the quarter. It reported no material changes to previously disclosed risk factors.
Important facts for investors to verify
- Actual vaccine orders, deliveries, revenue recognition and cash collections under APAs—particularly the status and revised terms, if any, of the Gavi agreement.
- Progress on U.S. regulatory review, FDA analytical-method alignment, and the manufacturing and quality requirements of other regulators.
- Whether the low reported cost of sales persists as pre-approval, reduced-cost inventory is used, and the effect on margins when inventory is valued at standard cost.
- Cash use, inventory buildup, deferred-revenue conversion, capital spending and ability to meet manufacturing and delivery commitments.
- Resolution and potential financial effects of the Par arbitration and shareholder litigation; disclosed loss estimates for these matters were unavailable or not reasonably estimable.
- Potential dilution from future stock issuance and the remaining capacity under the company’s $500 million at-the-market sales agreement (approximately $318 million at March 31, 2022).